VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 22, 2008) - Chemokine Therapeutics Corp. (the "Company") (TSX:CTI)(OTCBB:CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announces the engagement of Boenning & Scattergood Inc. as its exclusive advisor to assist the Company in the implementation of previously announced strategic financial initiatives.
